Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.

Bachanova V, Weisdorf DJ, Wang T, Marsh SG, Trachtenberg E, Haagenson MD, Spellman SR, Ladner M, Guethlein LA, Parham P, Miller JS, Cooley SA.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1602-7. doi: 10.1016/j.bbmt.2016.05.016. Epub 2016 May 21.

2.

Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation.

Ullah MA, Hill GR, Tey SK.

Front Immunol. 2016 Apr 15;7:144. doi: 10.3389/fimmu.2016.00144. eCollection 2016. Review.

3.

Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.

Rocha V, Ruggeri A, Spellman S, Wang T, Sobecks R, Locatelli F, Askar M, Michel G, Arcese W, Iori AP, Purtill D, Danby R, Sanz GF, Gluckman E, Eapen M; Eurocord, Cord Blood Committee Cellular Therapy Immunobiology Working Party of the European Group for Blood and Marrow Transplantation, Netcord, and the Center for International Blood and Marrow Transplant Research.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1284-9. doi: 10.1016/j.bbmt.2016.04.007. Epub 2016 Apr 16.

PMID:
27090957
4.

KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV.

Boudreau JE, Mulrooney TJ, Le Luduec JB, Barker E, Hsu KC.

J Immunol. 2016 Apr 15;196(8):3398-410. doi: 10.4049/jimmunol.1502469. Epub 2016 Mar 9.

PMID:
26962229
5.

Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Martner A, Rydström A, Riise RE, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB.

Oncoimmunology. 2015 May 5;5(1):e1041701. doi: 10.1080/2162402X.2015.1041701. eCollection 2016.

6.

Selection and expansion of natural killer cells for NK cell-based immunotherapy.

Becker PS, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, Tonn T, Seidl C.

Cancer Immunol Immunother. 2016 Apr;65(4):477-84. doi: 10.1007/s00262-016-1792-y. Epub 2016 Jan 25. Review.

7.

Cord Blood as a Source of Natural Killer Cells.

Mehta RS, Shpall EJ, Rezvani K.

Front Med (Lausanne). 2016 Jan 5;2:93. doi: 10.3389/fmed.2015.00093. eCollection 2015. Review.

8.

Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.

Shaffer BC, Le Luduec JB, Forlenza C, Jakubowski AA, Perales MA, Young JW, Hsu KC.

Biol Blood Marrow Transplant. 2016 Apr;22(4):705-9. doi: 10.1016/j.bbmt.2015.12.028. Epub 2016 Jan 6.

PMID:
26772158
9.

Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy.

Chester C, Fritsch K, Kohrt HE.

Front Immunol. 2015 Dec 2;6:601. doi: 10.3389/fimmu.2015.00601. eCollection 2015. Review.

10.

Agonist antibody that induces human malignant cells to kill one another.

Yea K, Zhang H, Xie J, Jones TM, Lin CW, Francesconi W, Berton F, Fallahi M, Sauer K, Lerner RA.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6158-65. doi: 10.1073/pnas.1519079112. Epub 2015 Oct 20.

11.

Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts.

Picardi A, Mengarelli A, Marino M, Gallo E, Benevolo M, Pescarmona E, Cocco R, Fraioli R, Tremante E, Petti MC, De Fabritiis P, Giacomini P.

J Exp Clin Cancer Res. 2015 Sep 11;34:98. doi: 10.1186/s13046-015-0213-y.

12.

Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.

Goldberg JL, Sondel PM.

Semin Oncol. 2015 Aug;42(4):562-72. doi: 10.1053/j.seminoncol.2015.05.012. Epub 2015 Jun 3. Review.

13.

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.

Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM.

Front Immunol. 2015 Jul 27;6:368. doi: 10.3389/fimmu.2015.00368. eCollection 2015. Review.

14.

Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.

Gras Navarro A, Björklund AT, Chekenya M.

Front Immunol. 2015 Apr 29;6:202. doi: 10.3389/fimmu.2015.00202. eCollection 2015. Review.

15.

Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.

Sobecks RM, Wang T, Askar M, Gallagher MM, Haagenson M, Spellman S, Fernandez-Vina M, Malmberg KJ, Müller C, Battiwalla M, Gajewski J, Verneris MR, Ringdén O, Marino S, Davies S, Dehn J, Bornhäuser M, Inamoto Y, Woolfrey A, Shaw P, Pollack M, Weisdorf D, Milller J, Hurley C, Lee SJ, Hsu K.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1589-96. doi: 10.1016/j.bbmt.2015.05.002. Epub 2015 May 8.

16.

Haematological malignancies: at the forefront of immunotherapeutic innovation.

Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ.

Nat Rev Cancer. 2015 Apr;15(4):201-15. doi: 10.1038/nrc3907. Epub 2015 Mar 19. Review.

17.

NK cell-based immunotherapies in Pediatric Oncology.

McDowell KA, Hank JA, DeSantes KB, Capitini CM, Otto M, Sondel PM.

J Pediatr Hematol Oncol. 2015 Mar;37(2):79-93. doi: 10.1097/MPH.0000000000000303. Review.

18.

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.

Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, Pittaluga S, Sabatino M, Stroncek DF, Wayne AS, Zhang H, Fry TJ, Mackall CL.

Blood. 2015 Jan 29;125(5):784-92. doi: 10.1182/blood-2014-07-592881. Epub 2014 Dec 1.

19.

Association between CTL Precursor Frequency to HLA-C Mismatches and HLA-C Antigen Cell Surface Expression.

Israeli M, Roelen DL, Carrington M, Petersdorf EW, Claas FH, Haasnoot GW, Oudshoorn M.

Front Immunol. 2014 Oct 27;5:547. doi: 10.3389/fimmu.2014.00547. eCollection 2014.

20.

HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation.

Petersdorf EW, Gooley TA, Malkki M, Bacigalupo AP, Cesbron A, Du Toit E, Ehninger G, Egeland T, Fischer GF, Gervais T, Haagenson MD, Horowitz MM, Hsu K, Jindra P, Madrigal A, Oudshoorn M, Ringdén O, Schroeder ML, Spellman SR, Tiercy JM, Velardi A, Witt CS, O'Huigin C, Apps R, Carrington M; International Histocompatibility Working Group in Hematopoietic Cell Transplantation.

Blood. 2014 Dec 18;124(26):3996-4003. doi: 10.1182/blood-2014-09-599969. Epub 2014 Oct 16.

Items per page

Supplemental Content

Write to the Help Desk